LEONARD POST - 30 Sep 2025 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Role
Director
Signature
/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post
Issuer symbol
CGON
Transactions as of
30 Sep 2025
Transactions value $
-$197,450
Form type
4
Filing time
01 Oct 2025, 17:07:18 UTC
Previous filing
16 Sep 2025
Next filing
15 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
POST LEONARD E Director C/O CG ONCOLOGY, INC., 400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE /s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post 01 Oct 2025 0001235862

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGON Common Stock Options Exercise $3K +5K $0.60 5K 30 Sep 2025 Direct
transaction CGON Common Stock Sale -$200K -5K -100% $40.09 0 30 Sep 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGON Director Stock Option (right to buy) Options Exercise $0 -5K -4.03% $0.00 119K 30 Sep 2025 Common Stock 5K $0.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 Fully vested